Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pradip Bajgain

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Biorxiv : the Preprint Server for Biology|July 16, 2025
IL-7 armed binary CAR T cell strategy to augment potency against solid tumorsAlejandro G Torres Chavez, Mary K McKenna, Anmol Gupta, et al.
Frontiers in Immunology|August 14, 2025
IL-7 armed binary CAR T cell strategy to augment potency against solid tumorsAlejandro G Torres Chavez, Mary K McKenna, Anmol Gupta, et al.
Cancer Immunology Research|September 19, 2022
Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand-Expressing Solid TumorsPradip Bajgain, Alejandro G Torres Chavez, Kishore Balasubramanian, et al.
Cancer Discovery|June 9, 2018
Enhancing the Potency and Specificity of Engineered T Cells for Cancer TreatmentSujita Sukumaran, Norihiro Watanabe, Pradip Bajgain, et al.
Journal for Immunotherapy of Cancer|May 12, 2018
CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activationPradip Bajgain, Supannikar Tawinwung, Lindsey D'Elia, et al.
Oncoimmunology|February 10, 2017
Fine-tuning the CAR spacer improves T-cell potencyNorihiro Watanabe, Pradip Bajgain, Sujita Sukumaran, et al.
Molecular Therapy. Oncology|April 10, 2024
A dual-luciferase bioluminescence system for the assessment of cellular therapiesAlejandro G Torres Chavez, Mary K McKenna, Kishore Balasubramanian, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2017
Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic CancerSomala Mohammed, Sujita Sukumaran, Pradip Bajgain, et al.
Journal for Immunotherapy of Cancer|November 24, 2021
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancerSaisha A Nalawade, Paul Shafer, Pradip Bajgain, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 12, 2013
Kinetics of tumor destruction by chimeric antigen receptor-modified T cellsUsanarat Anurathapan, Robert C Chan, Hakeem F Hindi, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Biorxiv : the Preprint Server for Biology|July 16, 2025
IL-7 armed binary CAR T cell strategy to augment potency against solid tumorsAlejandro G Torres Chavez, Mary K McKenna, Anmol Gupta, et al.
Frontiers in Immunology|August 14, 2025
IL-7 armed binary CAR T cell strategy to augment potency against solid tumorsAlejandro G Torres Chavez, Mary K McKenna, Anmol Gupta, et al.
Cancer Immunology Research|September 19, 2022
Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand-Expressing Solid TumorsPradip Bajgain, Alejandro G Torres Chavez, Kishore Balasubramanian, et al.
Cancer Discovery|June 9, 2018
Enhancing the Potency and Specificity of Engineered T Cells for Cancer TreatmentSujita Sukumaran, Norihiro Watanabe, Pradip Bajgain, et al.
Journal for Immunotherapy of Cancer|May 12, 2018
CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activationPradip Bajgain, Supannikar Tawinwung, Lindsey D'Elia, et al.
Oncoimmunology|February 10, 2017
Fine-tuning the CAR spacer improves T-cell potencyNorihiro Watanabe, Pradip Bajgain, Sujita Sukumaran, et al.
Molecular Therapy. Oncology|April 10, 2024
A dual-luciferase bioluminescence system for the assessment of cellular therapiesAlejandro G Torres Chavez, Mary K McKenna, Kishore Balasubramanian, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2017
Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic CancerSomala Mohammed, Sujita Sukumaran, Pradip Bajgain, et al.
Journal for Immunotherapy of Cancer|November 24, 2021
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancerSaisha A Nalawade, Paul Shafer, Pradip Bajgain, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 12, 2013
Kinetics of tumor destruction by chimeric antigen receptor-modified T cellsUsanarat Anurathapan, Robert C Chan, Hakeem F Hindi, et al.
Pageof 2